DEP domain containing 1 (DEPDC1) protein is a novel oncoantigen upregulated in multiple types of cancers which present oncogenic activity and high immunogenicity. However, the function and therapeutic potential of DEPDC1 in hepatocellular carcinoma (HCC) remain unclear. In the present study, we showed that DEPDC1 was frequently upregulated in HCC and associated with cancer diagnosis and poor prognosis for HCC patients. Moreover, DEPDC1 promotes HCC cell proliferation in vitro as well as carcinogenesis in vivo. Notably, DEPDC1 overexpression also increases the neoplasm metastasis ability of HCC cells both in vivo and in vitro. Gene set enrichment analysis results showed that DEPDC1 expression is positively correlated with K-RAS signal pathway, pathways in cancer and WNT/β-catenin signal pathway, all of which are closely associated with specific cancer-related gene sets. Our study provides the basis for further investigation of the molecular mechanism by which DEPDC1 promotes the development and metastasis of HCC.
K E Y W O R D S
carcinogenesis, cell proliferation, DEP domain containing 1 protein, hepatocellular carcinoma, neoplasm metastasis identified 331 upregulated TF genes and 72 downregulated TF genes in HCC tissue. Among the genes identified, 110 TF correlated with poor patient prognosis. Furthermore, we found DEP domain containing 1 (DEPDC1) most significantly associated with overall patient survival, and that DEPDC1 can serve as a biomarker for HCC diagnosis.
Notably, DEPDC1 was further shown to have a biological signature in hepatocarcinogenesis validated by in vivo and in vitro experimental validation. Our results demonstrate a novel mechanism for the oncogenic role of DEPDC1 in HCC and suggest DEPDC1 as a potential therapeutic target. 
| MATERIAL S AND ME THODS

| Tissue specimens
| Cell culture
SMMC-7721, SK-HEP-1 and HEK-293T cells were obtained from Harbin Medical University (Harbin, China). All cell lines were cultured in DMEM (Gibco, New York, NY, USA). All cells were cultured at humidified 37°C with a 5% CO 2 atmosphere in DMEM supplemented with 10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin.
| Quantitative real-time PCR
Cell lines and tissue total RNA were extracted using TRIzol reagent (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer's instructions. Complementary DNA was synthesized using the PrimeScriptRT reagent kit (TaKaRa Bio, Tokyo, Japan). Quantitative real-time PCR (qPCR) was carried out using an iQ5 machine and SYBR Premix Ex Taq II (TaKaRa). Relative gene expression from cell lines was calculated and normalized to β-actin.
Relative genomic level of tumor tissues was compared with that of normal liver tissues. The primers that were used are listed in Supporting Information Table S1 .
| Western blot analysis
Proteins were separated by SDS-PAGE and transferred to nitrocellulose membrane (Bio-Rad, Hercules, CA, USA). Thereafter, membranes were blocked in PBS/Tween-20 containing 5% non-fat milk and incubated with the indicated primary antibodies. Proteins were detected using ECL reagents (Thermo Fisher Scientific). The primary antibodies used were anti-DEPDC1 (Cell Signaling Technology, Beverly, MA, USA) and anti-β-actin (ProteinTech Group, Chicago, IL, USA).
| shRNA stable expression
Three shRNA retroviruses targeting human DEDPC1 and a control shRNA retrovirus were constructed using a three-plasmid packaging system. Briefly, the lentiGuide-Puro (lenti-gRNA, #52963; Addgene, Watertown, MA, USA) vector expressing the shRNA sequence was cotransfected into HEK-293T cells. After 48 hours of incubation, the viral supernatant was collected and used to transduce cells in the presence of 10 μg/mL polybrene (Sigma Aldrich, St Louis, MO, USA). The infected cells were selected with puromycin (1 μg/mL) for 1 week to generate stable shRNA-expressing cancer cells and then continuously cultured with 0.5 μg/mL puromycin. The sh-RNA sequence that was used is listed in Supporting Information Table S2 . 
| Lentivirus production and infection
| Cell proliferation and colony formation assays
Cell proliferation assay was measured using CCK-8 (Dojindo, Kyushu, Japan) at 1, 3, and 5 days after lenti-DEPDC1 or lenti-vector SMMC-7721 infection. Cells were seeded into a 96-well plate at a density of 1500 cells/well, and 10 μL CCK-8 was added to 90 μL culture medium per well. The cells were subsequently incubated at 37°C for 2 hours, and optical density was measured at 450 nm. For colony formation assays, 1000 cells were seeded into each well of a six-well plate. Approximately 14 days after culturing, the cells were stained with 0.1% crystal violet and 20% methanol. Images were taken and the colonies were counted. and imaged using an inverted microscope (Olympus, Tokyo, Japan).
| In vivo assays for tumor formation
| In vitro migration and invasion assays
| In vivo assays for metastasis
For the in vivo metastasis assays, 2 × 10 6 SMMC-7721 cells with lenti-DEPDC1 or lenti-vector transfection were mixed in 0.2 mL serum-free DMEM and s.c. injected into nude mice liver (female BALB/c-nu/nu mice, 10 per group). After 60 days, the mice were killed, and their livers and lungs were dissected, then fixed with phosphate-buffered neutral formalin, and prepared for standard histological examination. Number of metastatic foci in liver and lung was determined using H&E staining in tissue sections under a binocular microscope (Olympus).
| Survival and hazard analysis
Expression levels of all HCC samples for each selected TF gene were used to investigate whether the expression level of a given TF gene is associated with prognosis in HCC patients. All HCC samples were dichotomized into two groups using the median expression level for each gene. Kaplan-Meier analysis was used to evaluate the overall survival time for the two groups. Differences in the survival times were compared using the log-rank test. Univariate Cox analysis and multivariate Cox proportional hazards regression model were used to determine the independent factors that influenced survival and recurrence based on the investigated variables.
| Gene set enrichment analysis
Gene set enrichment analysis (GSEA) was used to identify genes 
| Statistical analysis
Student's t test and Mann-Whitney test were used after using the Shapiro-Wilk test to determine data normality. Distributions of data were expressed as mean ± SD. P-value < .05 was considered statistically significant. Two-way ANOVA was used to analyze differences in the CCK-8 results between groups.
Diagnostic efficiency of DEPDC1 and alpha-fetoprotein (AFP) was evaluated by ROC (receiver operating characteristic curve). In addition, the Youden's index was generated to evaluate the optimized cut-off point and calculate the exact sensitivity and specificity of the variable. Comparison of two ROC curves and the area under the curve (AUC) 95% confidence intervals were calculated according to the DeLong method. All statistical analyses were carried out using R language (version 3.4.2, Auckland, New Zealand);
The following R packages were used in this study: "pROC", "ROCR", "rms", "survival", and "pheatmap". Figure 1A ; Table S3 ).
| RE SULTS
| Transcription factor genes differentially expressed in LIHC samples
To investigate the roles of TF in HCC patients for prognosis evaluation, an overall survival analysis was carried out to determine the association of these differentially expressed TF and patients' survival time. Three hundred seventy TCGA clinical characteristics and whole TF expression profiles were used for survival analyses.
Samples were classified into two groups according to the median gene expression level for each TF, and the difference of accumulated survival curves between two groups was carried out by KaplanMeier analysis (see Methods). As a result, 10 downregulated and 100 upregulated TF genes were significantly correlated with overall survival (P < .05, log-rank test, Figure 1B ). Somatic mutation frequencies of all the significantly expressed TF genes in TCGA are also shown in Figure 1B . Additionally, we investigated a possible correlation between clinical characteristics and tumor DEPDC1 expression level in TCGA LIHC patients. Results showed that patients with high DEPDC1 expression level had significant correlation with poorly differentiated tumors and high AFP level ( Figure 1C ).
| DEP domain containing 1 is frequently upregulated in HCC and is associated with cancer diagnosis and poor prognosis in HCC patients
To compare the expression level of DEPDC1 in HCC tissues and normal tissues, we carried out real-time PCR on 24 HCC biopsy tissues and 24 paired liver tissues of healthy controls. DEPDC1 was significantly upregulated at the mRNA level in HCC samples compared with normal liver tissues (P < .001, Figure 2A ). Kaplan-Meier survival analysis showed that HCC patients with high DEPDC1 expression had poorer outcomes (P < .001, Figure 2B ). Moreover, multivariate cox regression analysis constructed by these three independent factors showed that HCC patients with a high expression level of DEPDC1 in tumors harbored a 1.238-fold high risk of death (95% CI, 1.105-1.387, P-value = 2.27e-04) ( Figure 2C ).
We then investigated the utility of DEPDC1 for HCC diagnostic prediction compared with the traditional diagnostic biomarker AFP. In bio-proven HCC patients, normalized expression level (Δct normalized by β-actin) of DEPDC1 from RT-PCR and serum AFP level (ng/mL) was used to construct a ROC curve to evaluate the diagnostic efficiency in HCC. As a result, DEPDC1 has a higher diagnostic sensitivity and specificity than AFP for HCC diagnosis (AUC 0.8785 vs 0.6875, P < .05, Figure 2D ). Thus, these results showed that upregulated expression of DEPDC1 is an independent unfavorable prognostic factor in HCC and can serve as an excellent biomarker for HCC diagnosis.
| DEP domain containing 1 promotes HCC cell proliferation and tumorigenicity in vitro and in vivo
To further investigate the effects of DEPDC1 on HCC cell proliferation and tumorigenicity, we knocked down DEPDC1 expression through shRNA-mediated silencing in two different HCC cell lines, 
| DEP domain containing 1 promotes HCC cell invasion and migration in vitro and in vivo
To determine the effect of DEPDC1 on cell metastasis, Transwell migration and invasion assays were carried out in vitro. Results Results showed that DEPDC1 significantly increased the metastatic ability of SMCC-7721 in vivo ( Figure 4C,D) . 
| D ISCUSS I ON
Several studies have shown that DEPDC1 is aberrantly overexpressed in diverse human cancers and acts as an oncogene in tumorigenesis and tumor progression. [23] [24] [25] [26] In a previous study, Feng et al 27 reported that DEPDC1 is essentially required for accelerating cell cycle progression and motility in nasopharyngeal carcinoma through the NF-κB signal pathway. In another study, researchers discovered an oncogenic role of DEPDC1 in prostate cancer through activation of E2F signaling which has a broad impact on HCC progression. Alpha-fetoprotein is a traditional biomarker for prognostic assessment and early diagnosis of HCC. However, its low sensitivity renders it inadequate to identify all patients that will develop HCC. 30 In the present study, DEPDC1 expression level had a higher diagnostic sensitivity and specificity than AFP for detecting HCC patients, which confirmed the utility of a combined diagnostic method by DEPDC1 and AFP in HCC diagnosis and prognosis. 26 In addition,
we confirmed the role of DEPDC1 in proliferation and metastasis by using lentivirus knockdown and overexpression systems as well as in vivo experiments to further verify our in vitro results ( Figure S2 ).
For a preliminary exploration of the DEPDC1 oncogenic mechanism in HCC, we developed SMMC-7721 sh-DEPDC1 and sh-control cells and then undertook RNA-seq analysis. GSEA of the RNA-seq data showed that the K-RAS, WNT/β-catenin signal pathway, and pathways in cancer were differentially enriched, which promote tumorigenesis, cell metastasis and cell proliferation in HCC. 31, 32 These results demonstrated that DEPDC1 might promote HCC cell proliferation and metastasis through activation of these signaling pathways. However, further investigation of the molecular mechanisms of DEDPC1 is necessary.
F I G U R E 5
Gene set enrichment analysis of DEP domain containing 1 (DEPDC1)-regulated cancer-related pathways. A-C, Genes involved in the Kyoto Encyclopedia of Genes and Genomes (KEGG) K-RAS signal pathway, pathways in cancer and WNT/β catenin signal pathway showed significant change in DEPDC1 shRNA or control in SMMC-7721 cell based on RNA sequencing. Normalized enrichment scores (NES) for each gene and the value of the ranking metric moving down or moving up the list of ranked genes is shown. D, Real-time PCR analysis shows a significant decrease in the expression levels of MMP9, WNT6, RAC2, NR4A2, PRODH, SEPP1, EDN2, LYPD3, WNT1, PTCH1, NKD1, CTNNB1 and CCND2 in SMMC-7721 cells infected with sh-DEPDC1. ***P < 0.001
In conclusion, we showed that DEPDC1 regulates HCC cell proliferation and metastasis both in vivo and in vitro. Low expression of DEPDC1 correlated with repression of oncogenic pathways. Our study provided a new way to investigate the molecular mechanism by which DEPDC1 influences HCC progression and gives a potential therapeutic target for HCC treatment.
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